What is Immuron?
Founded in 1994, Immuron is a publicly listed Australian biopharmaceutical company dedicated to the development and commercialization of orally delivered targeted polyclonal antibodies. The company's primary focus lies in treating inflammatory-mediated and infectious diseases. Immuron's innovative approach aims to provide novel therapeutic options for a range of challenging health conditions, positioning it within the competitive landscape of biopharmaceutical research and development.
How much funding has Immuron raised?
Immuron has raised a total of $26.1M across 2 funding rounds:
Stock Offering
$6.1M
Other Financing Round
$20M
Stock Issuance/Offering (2017): $6.1M, investors not publicly disclosed
Other Financing Round (2020): $20M, investors not publicly disclosed
What's next for Immuron?
The substantial enterprise-level funding and recent strategic investment indicate Immuron's transition into a scaling phase, likely prioritizing clinical trial progression and market penetration for its lead candidates. This capital infusion is expected to accelerate the company's research and development efforts, potentially leading to key milestones in regulatory approvals and commercialization. Immuron's strategic focus on orally delivered antibodies suggests a commitment to enhancing patient compliance and therapeutic efficacy, a key differentiator in the biopharmaceutical market.
See full Immuron company page
